Multivalent in vivo delivery of DNA-encoded bispecific T cell engagers effectively controls heterogeneous GBM tumors and mitigates immune escape-Reference-Cited by-同舟云学术

Multivalent in vivo delivery of DNA-encoded bispecific T cell engagers effectively controls heterogeneous GBM tumors and mitigates immune escape

Published:2023-03 Issue: Volume:28 Page:249-263
ISSN:2372-7705
Container-title:Molecular Therapy - Oncolytics
language:en
Short-container-title:Molecular Therapy - Oncolytics

Author:

Park Daniel H.^ORCID,Liaw Kevin,Bhojnagarwala Pratik,Zhu Xizhou,Choi Jihae,Ali Ali R.,Bordoloi Devivasha,Gary Ebony N.,O’Connell Ryan P.,Kulkarni Abhijeet,Guimet Diana,Smith Trevor,Perales-Puchalt Alfredo,Patel Ami,Weiner David B.^ORCID

Publisher

Elsevier BV

Subject

Pharmacology (medical),Cancer Research,Oncology,Molecular Medicine

Reference35 articles.

1. Glioblastoma multiforme: an overview of emerging therapeutic targets;Taylor;Front. Oncol.,2019

2. Immunotherapy for glioblastoma: the promise of combination strategies;Bausart;J. Exp. Clin. Cancer Res.,2022

3. Epidermal growth factor receptor variant III (EGFRvIII) positivity in EGFR-amplified glioblastomas: prognostic role and comparison between primary and recurrent tumors;Felsberg;Clin. Cancer Res.,2017

4. Current therapeutic advances targeting EGFR and EGFRvIII in glioblastoma;Padfield;Front. Oncol.,2015

5. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma;O'Rourke;Sci. Transl. Med.,2017

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Format-tuning of in vivo-launched bispecific T cell engager enhances efficacy against renal cell carcinoma;Journal for ImmunoTherapy of Cancer;2024-06

2. Camelid‐derived Tcell engagers harnessing human γδ T cells as promising antitumor immunotherapeutic agents;European Journal of Immunology;2024-05-28

3. Siglec-7 glyco-immune binding mAbs or NK cell engager biologics induce potent antitumor immunity against ovarian cancers;Science Advances;2023-11-03

4. Mechanism-based pharmacokinetic and pharmacodynamic modeling for bispecific antibodies: challenges and opportunities;Expert Review of Clinical Pharmacology;2023-09-24

5. Bispecific T-Cell Engagers and Chimeric Antigen Receptor T-Cell Therapies in Glioblastoma: An Update;Current Oncology;2023-09-15